Sacituzumab govitecan: past, present and future of a new antibody–drug conjugate and future horizon
Abstract
Sacituzumab govitecan (SG) is a new antibody–drug conjugate directed against the cell-surface antigen Trop-2. Characteristics of the linker connecting the payload SN-38 to the antibody allows SG to kill tumor cells expressing Trop-2 and also the adjacent tumor cells (bystander effect). SG showed efficacy and safety in several epithelial tumors. The phase III ASCENT trial led to the approval of SG (10 mg/kg, d1,8 q3w) in patients with advanced or metastatic triple-negative breast cancer (TNBC) who have received ≥2 prior systemic therapies, including ≥1 for metastatic disease. The phase III TROPiCS-02 trial in heavily pretreated advanced hormone receptor (HR)-positive breast cancer has recently shown an improvement in progression-free survival for patients treated with SG compared to single-agent chemotherapy. The phase III post-neoadjuvant SASCIA study in early high-risk TNBC and HR-positive breast cancer is currently recruiting patients.
Plain language summary
Sacituzumab govitecan is a new treatment for metastatic triple-negative breast cancer. Triple-negative means that the three most commonly identified proteins are not found on the surface of cancer cells (estrogen or progesterone receptor and high level of the protein HER2). Metastatic breast cancer indicates that the breast cancer has spread to other parts of the body. Sacituzumab govitecan is a monoclonal antibody, a therapeutic antibody or protein that can attach a specific target on the surface of cancer cells known as Trop-2. The antibody carries a medication known as SN-38, which is released within and around the cancer cells, causing the destruction of cancer cells. The ASCENT trial compared 3 acituzumab govitecan with chemotherapy, which is a treatment that kills cancer cells or stops them from dividing. The trial showed that patients with advanced triple-negative breast cancer who took sacituzumab govitecan lived longer than those who took a different chemotherapy regimen while on the study. The TROPiCS-02 trial showed that also patients with a metastatic cancer expressing estrogen or progesterone receptor, known as hormone-receptor positive breast cancer, derived benefit from sacituzumab govitecan. The SASCIA trial will define if patients with early breast cancer receiving sacituzumab govitecan after surgery might live longer without the recurrence of cancer. Early-stage breast cancer means that the cancer has not spread to other parts of the body and can be completely removed with surgery.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Strategies and challenges for the next generation of antibody-drug conjugates. Nat. Rev. Drug Discov. 16, 315–337 (2017).
- 2. . Antibody-drug conjugates in solid tumors: a look into novel targets. J. Hematol. Oncol. 14(1), 20 (2021).
- 3. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66(6), 3214–3221 (2006).
- 4. . Antibody–drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9, 33–46 (2018).
- 5. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 76(9), 2710–2719 (2016).
- 6. Trastuzumab emtansine for HER2- positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).
- 7. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 689–699 (2014).
- 8. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380, 617–628 (2019).
- 9. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med. 382, 610–621 (2020).
- 10. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J. Clin. Oncol. 37, 2592–2600 (2019).
- 11. ASCENT clinical trial investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 384(16), 1529–1541 (2021). •• Phase III confirmatory study showing an improvement in PFS and OS with sacituzumab govitecan compared to single-agent chemotherapy for patients with metastatic triple-negative breast cancer.
- 12. . Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 78, 5147–5150 (1981).
- 13. . Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer 6, 84–105 (2015).
- 14. . Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci. Rep. 6, 33658 (2016). • TROP2 overexpression is associated with poor survival in human solid tumors.
- 15. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 32(2), 222–233 (2013).
- 16. . Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin. Cancer Res. 11(12), 4357–4364 (2005).
- 17. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann. Oncol. S0923-534(21)02047-0 (2021). • Sacituzumab govitecan benefits patients with previously treated mTNBC expressing high/medium Trop-2 compared with standard of care chemotherapy and regardless of germline BRCA1/2 mutation status.
- 18. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J. Clin. Oncol. 35(19), 2141–2148 (2017).
- 19. . The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 9(48), 28989–29006 (2018).
- 20. Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. Exp. Mol. Pathol. 94(1), 73–78 (2013).
- 21. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 26(5), 919–931 (2015).
- 22. . Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget 6(26), 22496–22512 (2015).
- 23. First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin. Cancer Res. 21(17), 3870–3878 (2015).
- 24. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer 123(19), 3843–3854 (2017).
- 25. Sacituzumab govitecan, a trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann. Oncol. 32(6), 746–756 (2021).
- 26. . Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol. Cancer Ther. 12(6), 968–978 (2013).
- 27. CAMPTOSAR®(Irinotecan) Injection, intravenous infusion. Prescribing information. Last update: April 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020571s048lbl.pdf
- 28. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin. Cancer Res. 21(22), 5131–5138 (2015).
- 29. Abstract 3193: treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51. Cancer Res. 77(13), 3193 (2017).
- 30. . Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann. Oncol. 23(6), vi46–vi51 (2012).
- 31. . Triple-negative breast cancer: advancements in characterization and treatment approach. Curr. Opin. Obstet. Gynecol. 28, 59–69 (2016).
- 32. ESMO, FDA grants breakthrough therapy designation for sacituzumab govitecan for the treatment of TNBC; https://www.esmo.org/oncology-news/archive/fda-grants-breakthrough-therapy-designation-for-sacituzumab-govitecan-for-the-treatment-of-tnbc
- 33. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N. Engl. J. Med. 380(8), 741–751 (2019).
- 34. Sacituzumab govitecan in previously treated hormone receptor-positive /HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann. Oncol. 31(12), 1709–1718 (2020).
- 35. Therapy of advanced non-small cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. J. Clin. Oncol. 35, 2790–2797 (2017).
- 36. Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan. Clin. Cancer Res. 23, 5711–5719 (2017).
- 37. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): results from a phase I/II study. J. Clin. Oncol. 37, 354 (2019).
- 38. Real-world 1-year survival analysis of patients with metastatic breast cancer with liver or lung metastasis treated with eribulin, gemcitabine or capecitabine. Ann. Oncol. 30, v133 (2019).
- 39. TROPiCS-02: a phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. Future Oncol. 16(12), 705–715 (2020).
- 40. Sacituzumab govitecan – FDA Access on September 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf
- 41. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J. Clin. Oncol. 39(22), 2474–2485 (2021).
- 42. U.S. Food & Drug Administration, FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer; www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sacituzumab-govitecan-advanced-urothelial-cancer
- 43. Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). J. Clin. Oncol. 39(15), 1080 (2021).
- 44. Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). J. Clin. Oncol. 39(15), 1011–1011 (2021).
- 45. Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer. Cancer Res. 81(4), PD13-07 (2021).
- 46. Assessment of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC). J. Clin. Oncol. 39(15), 1077 (2021).
- 47. U.S. Food & Drug Administration, FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer; https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer
- 48. SG Summary of Product Characteristics, version 24 November 2021. https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf
- 49. Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC). Ann. Oncol. 32(Suppl. 5), S457–S515 (2021). • Patients without TNBC at initial diagnosis had a significant survival benefit with sacituzumab govitecan vs treatment of physician's choice, with a manageable safety profile. Outcomes were similar to those of the ASCENT trial's overall population.
- 50. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer. J. Clin. Oncol. 40(Suppl. 17), LBA1001 (2022).
- 51. Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer. Cancer Res. 81(4), PS11-09 (2021). • Patients with UGT1A1 homozygous *28/*28 genotype treated with sacituzumab govitecan are at modestly higher risk for neutropenia and diarrhea and should be monitored closely.
- 52. Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Cancer Res. 81(4), GS3-06 (2021).
- 53. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities. Oncologist 26(10), 827–834 (2021).
- 54. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol. 3(10), 1378–1385 (2017).
- 55. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J. Clin. Oncol. 33, 13–21 (2015).
- 56. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res. Treat. 144, 223–232 (2014).
- 57. Utility of the CPS+EG staging system in hormone receptor positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. Eur. J. Cancer 53, 65–74 (2016).
- 58. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N. Engl. J. Med. 376, 2147–2159 (2017).
- 59. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380, 617–628 (2019).
- 60. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J. Clin. Oncol. 34, 1034–1042 (2016).
- 61. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N. Engl. J. Med. 377, 122–131 (2017).
- 62. Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC). J. Clin. Oncol. 36, 1004 (2018).
- 63. Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. J. Clin. Oncol. 39(15), TPS602 (2021).
- 64. Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment. Ann. Oncol. 33(Suppl. 3), S148–S164 (2022).
- 65. Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: results from the NeoSTAR trial. J. Clin. Oncol. 40(Suppl. 16), 512 (2022).
- 66. Datopotamab deruxtecan (Dato-DXd) in advanced/metastatic HER2 negative breast cancer: triple negative breast cancer results from the phase 1 TROPION-PanTumor01 study. Cancer Res. 82(Suppl. 4), GS1-05 (2022).